![]() | Up a level |
Diamond, Eli L., Subbiah, Vivek ORCID: 0000-0002-6064-6837, Lockhart, A. Craig, Blay, Jean-Yves
ORCID: 0000-0001-7190-120X, Puzanov, Igor, Chau, Ian, Raje, Noopur S., Wolf, Jurgen, Erinjeri, Joseph P., Torrisi, Jean, Lacouture, Mario, Elez, Elena
ORCID: 0000-0002-4653-6324, Martinez-Valle, Ferran, Durham, Benjamin
ORCID: 0000-0001-8090-5448, Arcila, Maria E., Ulaner, Gary, Abdel-Wahab, Omar, Pitcher, Bethany, Makrutzki, Martina, Riehl, Todd, Baselga, Jose and Hyman, David M.
(2018).
Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study.
JAMA Oncol., 4 (3).
S. 384 - 389.
CHICAGO:
AMER MEDICAL ASSOC.
ISSN 2374-2445
Diamond, Eli L., Subbiah, Vivek ORCID: 0000-0002-6064-6837, Lockhart, Craig, Blay, Jean-Yves
ORCID: 0000-0001-7190-120X, Faris, Jason E., Puzanov, Igor, Chau, Ian
ORCID: 0000-0003-0286-8703, Raje, Noopur S., Wolf, Juergen S., Erinjeri, Joe, Torrisi, Jean, Ulaner, Gary, Lacouture, Mario, Robson, Susan, Makrutzki, Martina, Elez, Elena, Tabernero, Josep, Abdel-Wahab, Omar, Baselga, Jose and Hyman, David M.
(2016).
Vemurafenib in Patients with Erdheim-Chester Disease (ECD) and Langerhans Cell Histiocytosis (LCH) Harboring BRAF(V600) Mutations: A Cohort of the Histology-Independent VE-Basket Study.
Blood, 128 (22).
WASHINGTON:
AMER SOC HEMATOLOGY.
ISSN 1528-0020
Hyman, David M., Puzanov, Igor, Subbiah, Vivek ORCID: 0000-0002-6064-6837, Faris, Jason E., Chau, Ian
ORCID: 0000-0003-0286-8703, Blay, Jean-Yves
ORCID: 0000-0001-7190-120X, Wolf, Juergen, Raje, Noopur S., Diamond, Eli L., Hollebecque, Antoine
ORCID: 0000-0003-2869-7551, Gervais, Radj, Elena Elez-Fernandez, Maria, Italiano, Antoine, Hofheinz, Ralf-Dieter, Hidalgo, Manuel, Chan, Emily, Schuler, Martin, Lasserre, Susan Frances, Makrutzki, Martina, Sirzen, Florin, Veronese, Maria Luisa, Tabernero, Josep
ORCID: 0000-0002-2495-8139 and Baselga, Jose
(2015).
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.
N. Engl. J. Med., 373 (8).
S. 726 - 737.
WALTHAM:
MASSACHUSETTS MEDICAL SOC.
ISSN 1533-4406
Hyman, David Michael, Blay, Jean-Yves ORCID: 0000-0001-7190-120X, Chau, Ian
ORCID: 0000-0003-0286-8703, Raje, Noopur S., Fernandez, Maria Elena Elez, Wolf, Juergen, Sirzen, Florin, Veronese, Maria Luisa, Mitchell, Lada, Puzanov, Igor and Baselga, Jose
(2014).
VE-BASKET, a first-in-kind, phase II, histology-independent basket study of vemurafenib (VEM) in nonmelanoma solid tumors harboring BRAF V600 mutations (V600m).
J. Clin. Oncol., 32 (15).
ALEXANDRIA:
AMER SOC CLINICAL ONCOLOGY.
ISSN 1527-7755
Kaley, Thomas, Touat, Mehdi, Subbiah, Vivek ORCID: 0000-0002-6064-6837, Hollebecque, Antoine, Rodon, Jordi, Lockhart, A. Craig, Keedy, Vicki, Bielle, Franck, Hofheinz, Ralf-Dieter, Joly, Florence, Blay, Jean-Yves
ORCID: 0000-0001-7190-120X, Chau, Ian, Puzanov, Igor, Raje, Noopur S., Wolf, Jurgen, DeAngelis, Lisa M., Makrutzki, Martina, Riehl, Todd, Pitcher, Bethany, Baselga, Jose and Hyman, David M.
(2018).
BRAF Inhibition in BRAF(V600)-Mutant Gliomas: Results From the VE-BASKET Study.
J. Clin. Oncol., 36 (35).
S. 3477 - 3487.
ALEXANDRIA:
AMER SOC CLINICAL ONCOLOGY.
ISSN 1527-7755
Subbiah, Vivek ORCID: 0000-0002-6064-6837, Puzanov, Igor, Blay, Jean-Yves
ORCID: 0000-0001-7190-120X, Chau, Ian
ORCID: 0000-0003-0286-8703, Lockhart, A. Craig, Raje, Noopur S., Wolf, Juergen, Baselga, Jose, Meric-Bernstam, Funda, Roszik, Jason
ORCID: 0000-0002-4561-6170, Diamond, Eli L., Riely, Gregory J., Sherman, Eric J., Riehl, Todd, Pitcher, Bethany and Hyman, David M.
(2020).
Pan-Cancer Efficacy of Vemurafenib in BRAF(V)(600)-Mutant Non-Melanoma Cancers.
Cancer Discov., 10 (5).
S. 657 - 664.
PHILADELPHIA:
AMER ASSOC CANCER RESEARCH.
ISSN 2159-8290
Tabernero, Josep, Chan, Emily, Baselga, Jose, Blay, Jean-Yves ORCID: 0000-0001-7190-120X, Chau, Ian
ORCID: 0000-0003-0286-8703, Hyman, David Michael, Raje, Noopur S., Wolf, Juergen, Sirzen, Florin, Veronese, Maria Luisa, Mitchell, Lada and Hidalgo, Manuel
(2014).
VE-BASKET, a Simon 2-stage adaptive design, phase II, histology-independent study in nonmelanoma solid tumors harboring BRAF V600 mutations (V600m): Activity of vemurafenib (VEM) with or without cetuximab (CTX) in. colorectal cancer (CRC).
J. Clin. Oncol., 32 (15).
ALEXANDRIA:
AMER SOC CLINICAL ONCOLOGY.
ISSN 1527-7755